Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lysozyme eye drops for ocular surface protection in new orthokeratology lens wearers
ChiCTR2100046119Phase 4Recruiting
- Sponsor
- Beijing Remote Vision Ophthalmology Outpatient Department
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of lysozyme and sodium hyaluronate in myopia and Ocular surface inflammation (2 arms), sponsored by Beijing Remote Vision Ophthalmology Outpatient Department. Primary endpoints: Bacterial detection rate in conjunctival sac at 2 months, Ocular surface disease index score and 2 more. Started May 2021; status: recruiting.
02
Drugs
lysozymesodium hyaluronate
03
Conditions
myopiaOcular surface inflammation
Beyond the preview
Go deeper on ChiCTR2100046119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046119.